Published in Br J Cancer on March 20, 2014
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog (2014) 1.02
A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol (2014) 0.85
Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol (2014) 0.85
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling. J Cheminform (2015) 0.83
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open (2015) 0.80
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc (2016) 0.77
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol (2016) 0.76
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer (2016) 0.75
Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol (2016) 0.75
Barrett's Esophagus: Diagnosis and Management. Gastrointest Endosc (2017) 0.75
Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Gastroenterol Clin North Am (2015) 0.75
Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis. Dig Dis Sci (2015) 0.75
From Heartburn to Barrett's Esophagus, and Beyond. World J Surg (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
Quantitative methods in the review of epidemiologic literature. Epidemiol Rev (1987) 7.40
Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol (1994) 6.01
Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA (1994) 5.80
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Bias in treatment assignment in controlled clinical trials. N Engl J Med (1983) 4.78
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer (2001) 3.02
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer (2002) 2.51
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Random-effects meta-analyses are not always conservative. Am J Epidemiol (1999) 2.32
Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer (2003) 1.99
Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci (2000) 1.93
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res (1999) 1.86
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer (2009) 1.61
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol (2001) 1.49
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res (2006) 1.32
Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2009) 1.29
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2006) 1.12
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology (2002) 1.09
Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med (1997) 1.08
Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther (2004) 1.05
A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis (2004) 1.00
Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut (2005) 0.97
Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci (2001) 0.96
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther (2011) 0.95
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol (2012) 0.95
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma. Dis Esophagus (2011) 0.89
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev (2009) 0.86
Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol (2005) 0.85
Resolving conflicting clinical trials: guidelines for meta-analysis. J Clin Epidemiol (1988) 0.82
Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats. Yonsei Med J (2007) 0.78